Ahngook Pharmaceutical and Sandoz Korea signed a joint sales agreement of asthma and COPD treatment inhaler 'Airflusal Forspiro'
On June 30, Ahngook Pharmaceutical and Sandoz Korea signed a joint sales agreement of asthma and COPD treatment inhaler 'Airflusal Forspiro'.
As a result, both Ahngook Pharmaceutical and Sandoz Korea will proceed with sales of 'Airflusal Forspiro' in general hospitals and clinics.
'Airflusal Fo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
